<DOC>
	<DOC>NCT01990261</DOC>
	<brief_summary>This study will evaluate the survival of non-small cell lung cancer (wild-type EGFR) participants treated with Tarceva after at least one failed chemotherapy treatment, and the impact of prior chemotherapy treatments.</brief_summary>
	<brief_title>A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adults &gt;/= 18 years Histologically documented locally advanced, metastatic, or recurrent nonsmall cell lung carcinoma with wildtype EGFR eligible for Tarceva treatment. At least one failed chemotherapy treatment. Unknown EGFR mutation status</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>